企業プロフィール
Guardant Health 株価・ニュース・カタリスト
- ティッカー:
- GH
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
174.75 USD (-2.02%)
終値
最終更新: 2026年10月1日
17.3B USD
時価総額
株価変動の要因
2026年10月1日 時点で GH は 2.02% 下落し、$174.75 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Precision Oncology Diagnostics Company
Guardant Health develops blood-based and tissue-based tests for cancer screening, treatment selection, and disease monitoring. Its platform analyzes cell-free DNA and other molecular signals, supported by large clinical datasets, machine learning, centralized laboratories, and regulatory-grade test development.
Advanced-Cancer Testing
Guardant360 tests profile tumor-derived alterations from blood to guide targeted therapy selection in advanced cancer. FDA-approved companion-diagnostic versions support specific oncology drugs, while broader laboratory-developed offerings help clinicians identify actionable mutations when tissue is unavailable or insufficient.
Molecular Residual Disease and Recurrence Monitoring
Guardant Reveal is designed to detect residual disease and recurrence risk after curative-intent treatment. The test extends the company's role from treatment selection in advanced cancer into longitudinal monitoring of patients with earlier-stage disease.
Cancer Screening
Shield is a blood-based colorectal cancer screening test intended to increase screening participation among average-risk adults. Its commercial model depends on primary-care adoption, guideline inclusion, laboratory scale, reimbursement, and the ability to reach patients who do not complete stool-based or endoscopic screening.
Biopharma and Data Services
Guardant works with pharmaceutical companies on clinical-trial testing, companion diagnostics, biomarker development, and real-world data. These collaborations use the same genomic platform and datasets that support clinical testing, creating a second revenue stream alongside physician-ordered tests.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。